Hiroshi Sheraton is an intellectual property (IP) and life sciences lawyer based in London. His practice includes handling IP disputes, most often internationally. Across technologies and industries, he has litigated patent cases throughout Europe, the Americas, and Asia. He has managed trademark and trade secret disputes alongside advising clients on strategic IP matters. Hiroshi’s deep understanding of the biotechnology and pharmaceutical industry has allowed him to represent clients in key licensing and collaboration deals for both licensors and licensees. He often counsels clients on regulatory exclusivities, orphan designations, and other IP-adjacent rights and the interface between IP and competition laws.
As part of his cross-border practice, Hiroshi represents clients in IP disputes in the UK and across Europe, including advising on the interaction between cases in the European Patent Office, national courts across Europe, and the Unified Patent Court (UPC). Hiroshi typically works with clients and local counsel to develop and implement strategies that mitigate risks and optimize outcomes.
Drawing on his first degree in biochemistry and molecular biology, Hiroshi has a particular focus in the life sciences sector and has worked extensively with biotech, vaccine, RNA, recombinant, and gene therapy technologies to protect, defend and commercialize IP rights. He has managed bet-the-company patent cases in high-stakes litigation as well as negotiated complex cross-border licensing deals.
In other sectors, Hiroshi has handled matters for medical device, electronics, telecommunications, engineering, automotive, transport, mining, energy, consumer products, fintech and green tech. He is well versed in protecting know-how and trade secrets where patent rights may be inappropriate and has worked with specialist tax advisors to leverage commercial opportunities while maximizing IP protections.
Many of Hiroshi’s matters sit at the interface between IP law and other legal disciplines such as regulatory and EU competition law. He led one of the first "reverse payment" patent settlement cases before the European courts and advised clients on antitrust constraints to IP licensing matters such as FRAND.
He also advises on pharmaceutical regulatory issues where they interact with traditional IP rights, such as matters concerning Supplementary Protection Certificates, data exclusivity, orphan designations and pediatric exclusivities.
In the brand protection arena, Hiroshi has handled litigation, registry disputes, anti-counterfeiting, parallel trade, and enforcement matters often in highly regulated industries such as life sciences, tobacco, alcohol beverage, and online gaming as well as cosmetics and consumer products.
Leading Individual, Intellectual Property: Patents (Contentious and Non-Contentious), The Legal 500 UK (2025)
Recommended, TMT (Technology, Media and Telecoms): Intellectual Property: Patents (Contentious and Non-Contentious), The Legal 500 UK (2025)
Listed, World Trademark Review 1000 (2022–2024)
Ranked, Intellectual Property, London, Chambers UK (2009–2025)
Ranked, Intellectual Property: Patent Litigation, London, Chambers UK (2020–2025)
Listed, Managing Intellectual Property, Patent Star, United Kingdom (England) (2024)
Listed, Managing Intellectual Property, Trademark Star, United Kingdom (England) (2024)
Member, Intellectual Property Lawyers Association
Associate Member, Chartered Institute of Trade Mark Attorneys
Member, Law Society of England & Wales
Associate Member, Chartered Institute of Patent Attorneys